VERACYTE INC (VCYT) Stock Overview
USA - NASDAQ:VCYT - US92337F1075 - Common Stock
VCYT Key Statistics, Chart & Performance
The current stock price of VCYT is 35.33 USD. In the past month the price decreased by -0.84%. In the past year, price increased by 2.97%.
VCYT Latest News, Press Relases and Analysis
VCYT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Related stock screener links
About VCYT
Company Profile
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 824 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Company Info
VERACYTE INC
6000 Shoreline Court, Suite 300
South San Francisco CALIFORNIA 94080 US
CEO: Bonnie H. Anderson
Employees: 824
Phone: 16502436300
VERACYTE INC / VCYT FAQ
What does VCYT do?
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 824 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
What is the current price of VCYT stock?
The current stock price of VCYT is 35.33 USD. The price decreased by -0.23% in the last trading session.
Does VERACYTE INC pay dividends?
VCYT does not pay a dividend.
How is the ChartMill rating for VERACYTE INC?
VCYT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the market expecting VCYT stock to perform?
17 analysts have analysed VCYT and the average price target is 42.05 USD. This implies a price increase of 19.01% is expected in the next year compared to the current price of 35.33.
Can you provide the number of employees for VERACYTE INC?
VERACYTE INC (VCYT) currently has 824 employees.
VCYT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VCYT. When comparing the yearly performance of all stocks, VCYT is one of the better performing stocks in the market, outperforming 83.89% of all stocks.
VCYT Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to VCYT. VCYT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
VCYT Financial Highlights
Over the last trailing twelve months VCYT reported a non-GAAP Earnings per Share(EPS) of 0.33. The EPS increased by 144% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.5% | ||
| ROA | 1.96% | ||
| ROE | 2.16% | ||
| Debt/Equity | 0 |
VCYT Forecast & Estimates
17 analysts have analysed VCYT and the average price target is 42.05 USD. This implies a price increase of 19.01% is expected in the next year compared to the current price of 35.33.
For the next year, analysts expect an EPS growth of 25.8% and a revenue growth 12.84% for VCYT